Boehringer Ingelheim

This sponsor has funded 122 studies across 101 countries.

PAS funded by this sponsor.
EU PAS ID Status Title Protocol uploaded Results uploaded
3061 Finalised No Yes
3064 Finalised No Yes
4290 Finalised No No
4373 Finalised No No
5214 Finalised No Yes
5790 Ongoing No No
5855 Finalised No Yes
6134 Finalised No Yes
6352 Finalised No No
6568 Planned No No
6616 Finalised No No
6804 Finalised Yes No
7591 Finalised Yes Yes
7727 Finalised No No
8525 Finalised Yes Yes
9111 Finalised No Yes
9364 Ongoing No No
9374 Ongoing Yes No
9771 Ongoing No No
10457 Finalised No No
10945 Ongoing No No
11368 Ongoing Yes No
11885 Finalised No No
11924 Ongoing No No
12709 Finalised No No
12750 Finalised No No
12795 Ongoing No No
12864 Ongoing No No
12878 Ongoing No No
12954 Ongoing No No
13167 Ongoing Yes No
13390 Finalised Yes Yes
13413 Finalised Yes Yes
13605 Ongoing No No
13627 Ongoing No No
13672 Finalised No Yes
14507 Finalised Yes Yes
14956 Finalised No No
15008 Planned Yes No
16314 Planned No No
16424 Ongoing Yes No
16528 Finalised No No
16629 Planned No No
16988 Finalised No Yes
17055 Finalised Yes Yes
17078 Finalised Yes Yes
17165 Finalised Yes Yes
17386 Finalised Yes Yes
17922 Planned No No
18150 Planned Yes No
18745 Finalised No No
19384 Finalised No Yes
19558 Ongoing No No
19865 Ongoing No No
20025 Ongoing Yes No
20677 Ongoing No No
21037 Finalised No No
21422 Planned No No
21548 Ongoing No No
21574 Finalised Yes Yes
21696 Ongoing Yes No
21699 Finalised No Yes
22002 Finalised Yes No
23589 Planned No No
24004 Ongoing No No
25626 Ongoing No No
25682 Planned No No
26211 Ongoing Yes No
26481 Ongoing No No
27606 Finalised Yes Yes
28505 Finalised No Yes
29401 Planned No No
29784 Ongoing No No
29889 Ongoing Yes No
29985 Ongoing Yes No
30039 Finalised Yes No
30087 Planned Yes No
30293 Finalised Yes No
30838 Ongoing No No
30851 Finalised No No
31146 Ongoing No No
31932 Planned No No
31940 Planned No No
31950 Ongoing No No
32098 Planned No No
32329 Ongoing No No
32862 Ongoing No No
33011 Planned No No
33426 Ongoing No No
33970 Planned No No
33973 Planned No No
34689 Ongoing No No
34861 Finalised Yes Yes
35014 Finalised Yes Yes
35224 Ongoing Yes No
35286 Ongoing No No
37649 Planned No No
38023 Planned No No
38026 Planned No No
38272 Ongoing No No
39461 Finalised Yes Yes
39494 Finalised Yes No
40026 Finalised No Yes
41157 Finalised Yes Yes
41509 Planned No No
42653 Planned No No
43164 Finalised Yes Yes
43167 Ongoing No No
44101 Ongoing No No
44267 Finalised Yes Yes
44579 Ongoing No No
44641 Planned No No
45682 Ongoing No No
46175 Finalised Yes No
47537 Finalised Yes No
47909 Planned No No
48472 Finalised No No
49653 Planned No No
103733 Planned No No
106700 Planned No No
106763 Planned No No
106792 Planned No No

PAS by Risk Management Plan (RMP) requirement

Boehringer Ingelheim

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.